Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Advertising

Press Releases

40 Press Releases
DateTitleCompany
09 Oct 17 ThromboGenics announces publication in Experimental Eye Research of preclinical data supporting therapeutic potential of THR-317 in DR ThromboGenics NV,
Published by
GlobeNewswire
28 Sep 17 ThromboGenics NV : ThromboGenics Successfully Introduces New 'Already-Diluted' Formulation of JETREA® (ocriplasmin) in the US ThromboGenics NV,
Published by
GlobeNewswire
28 Sep 17 ThromboGenics NV : ThromboGenics Presenting THR-687 Preclinical Data at European Association for Vision and Eye Research (EVER) Meeting ThromboGenics NV,
Published by
GlobeNewswire
18 Sep 17 ThromboGenics NV : ThromboGenics Regains Global Rights to JETREA® (ocriplasmin) ThromboGenics NV,
Published by
GlobeNewswire
01 Sep 17 ONCURIOUS NV acquires unique portfolio of next-generation immuno-oncology assets from VIB ThromboGenics NV,
Published by
GlobeNewswire
16 Aug 17 New ThromboGenics' Ocriplasmin Clinical and Health Economic Data Presented at ASRS 2017 Annual Scientific Meeting in Boston ThromboGenics NV,
Published by
GlobeNewswire
10 Jul 17 ThromboGenics and BioInvent Amending Long-Standing Monoclonal Antibody Development Agreement ThromboGenics NV,
Published by
GlobeNewswire
15 Jun 17 ThromboGenics Long-time Non-executive Director Thomas Clay Appointed Chairman of the Board of Directors ThromboGenics NV,
Published by
GlobeNewswire
20 Apr 17 ThromboGenics Achieves Important Milestone in the Development of THR-149, A Novel Plasma Kallikrein Inhibitor for Diabetic Macular Edema ThromboGenics NV,
Published by
GlobeNewswire
01 Mar 16 ThromboGenics to Host R&D Investor Meeting on Novel Disease-Modifying Approaches for Diabetic Eye Disease 18 March in London ThromboGenics NV,
Published by
GlobeNewswire
13 Jan 16 ThromboGenics Enrolls First Patient in Phase II CIRCLE Trial ThromboGenics NV,
Published by
GlobeNewswire
07 Jan 16 Oncurious NV Announces FDA Acceptance of Investigational New Drug (IND) Application for a Phase I/IIa Study with TB-403 for the Treatment of Pediatric Brain Tumors ThromboGenics NV,
Published by
GlobeNewswire
18 Nov 15 ThromboGenics Reports Positive 2 Year Results from the OASIS Study with JETREA® (ocriplasmin) for the treatment of Symptomatic VMA/VMT and Macular Hole ThromboGenics NV,
Published by
GlobeNewswire
13 Nov 15 ThromboGenics Presents Full OASIS JETREA Trial Data Analysis (incl ERG) and Further Real World Clinical Data at Upcoming AAO 2015 in Las Vegas ThromboGenics NV,
Published by
GlobeNewswire
12 Nov 15 ThromboGenics Announces FDA Acceptance of Investigational New Drug (IND) Application for Phase II Study with JETREA® for the Treatment of Non-Proliferative Diabetic Retinopathy (CIRCLE) ThromboGenics NV,
Published by
GlobeNewswire
10 Sep 15 Baron Philippe Vlerick increases shareholding in ThromboGenics NV to 6.4% ThromboGenics NV,
Published by
GlobeNewswire
26 Jun 15 Oncurious NV Appoints Prof Dr Peter Carmeliet as its Chief Scientific Strategy Advisor ThromboGenics NV,
Published by
GlobeNewswire
23 Apr 15 ThromboGenics Starts Evaluating JETREA® for the Treatment of Retinal Vein Occlusion (RVO) ThromboGenics NV,
Published by
GlobeNewswire
10 May 12 ThromboGenics NV - Business Update ThromboGenics NV,
Published by
PR Newswire
24 Mar 15 ThromboGenics Announces Positive Topline Results from OASIS Study ThromboGenics NV,
Published by
GlobeNewswire
24 Mar 15 OASIS Study Clarification with regard to number of ERM Patients recruited ThromboGenics NV,
Published by
GlobeNewswire
07 Jan 15 ThromboGenics Appoints Dominique Vanfleteren as new Chief Financial Officer ThromboGenics NV,
Published by
GlobeNewswire
24 Feb 12 ThromboGenics to Present at the Citi 2012 Global Health Care Conference in New York ThromboGenics NV,
Published by
PR Newswire
17 Apr 12 ThromboGenics Resubmits BLA for Ocriplasmin with the FDA ThromboGenics NV
02 Mar 15 ThromboGenics Receives Positive CHMP Opinion for Ready Diluted Formulation of JETREA® ThromboGenics NV,
Published by
GlobeNewswire
22 Jan 15 ThromboGenics Appoints Emmanuèle Attout as Independent Non-Executive Director ThromboGenics NV,
Published by
GlobeNewswire
05 Feb 15 Thrombogenics Awarded €1.1 million IWT Research Grant ThromboGenics NV,
Published by
GlobeNewswire
05 Mar 15 ThromboGenics Appoints Dr Joseph Markoff as Scientific Advisor ThromboGenics NV,
Published by
GlobeNewswire
16 Mar 15 ThromboGenics' JETREA® Gains Approval in Brazil ThromboGenics NV,
Published by
GlobeNewswire
14 Apr 15 ThromboGenics and VIB launch New Oncology Company ThromboGenics NV,
Published by
GlobeNewswire
Advertising
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.